These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1315 related articles for article (PubMed ID: 19877724)

  • 21. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients.
    Hong T; Zhang M; Fan J
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD009698. PubMed ID: 26457607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Transplant Proc; 2019 Jun; 51(5):1424-1427. PubMed ID: 31060742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcineurin inhibitor-free protocols: risks and benefits.
    Barbari AG; Stephan AG; Masri MA
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety and efficacy of early withdrawal of calcineurin inhibitors in kidney transplant recipients 6 months' posttransplant.
    Boswell A; Evans L; Rigg K; Shehata M
    Transplant Proc; 2005 Mar; 37(2):884-5. PubMed ID: 15848564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
    Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
    J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppressive treatment and progression of histologic lesions in kidney allografts.
    Morales JM
    Kidney Int Suppl; 2005 Dec; (99):S124-30. PubMed ID: 16336565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates.
    Nakamura K; Oshima S; Maeda M; Morio H; Fukahori H; Nakanishi T; Tsujimoto S; Hirose J; Noto T; Hamakawa N; Inami M; Morokata T
    Int Immunopharmacol; 2018 Nov; 64():201-207. PubMed ID: 30195818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
    Zhang W; Fung J
    Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens.
    Merville P
    Drugs; 2005; 65(5):615-31. PubMed ID: 15748097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
    Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
    Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function.
    Weir MR; Blahut S; Drachenburg C; Young C; Papademitriou J; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Am J Nephrol; 2004; 24(4):379-86. PubMed ID: 15237243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
    Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL
    Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo sirolimus-based regimen in Thai renal transplant recipients.
    Townamchai N; Avihingsanon Y; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
    Transplant Proc; 2008 Sep; 40(7):2206-8. PubMed ID: 18790193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
    Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
    Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimizing calcineurin inhibitor drugs in renal transplantation.
    Flechner SM
    Transplant Proc; 2003 May; 35(3 Suppl):118S-121S. PubMed ID: 12742481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.